

Attachment 23: Phase IV Health Follow-Up IRB Approval Signature Pages

- 23.1) AHS Health Follow-Up Office of Protocol Services Continuing Review Approval
- 23.2) AHS Health Follow-Up Copernicus Group IRB Closeout Report



DATE: January 22, 2015

TO: Dale P Sandler, Ph.D.
Principal Investigator

THROUGH: Michael W Roberts, D.D.S., M.Sc.D.
Primary Reviewer

FROM: Resnik David, J.D., Ph.D.
Chair, NIEHS IRB

SUBJECT: IRB Review of Continuing Review 3/5/2015 for Protocol 11-E-N196:
"Agricultural Health Study: Health Followup"

Your Continuing Review 3/5/2015 was approved without stipulations by the NIEHS Institutional Review Board (IRB) at the January 08, 2015, meeting.

DISCUSSION:

Pesticides are a common environmental exposure due to their widespread use for agricultural, residential, and public health purposes. Farmers and their families represent a unique population for studying the chronic health effects of pesticides because farmers know what chemicals they use, furthermore, farmers tend to remain at the same location over most of their adult life. The Agricultural Health Study (AHS), a cohort of ~89,000 pesticide applicators and spouses from Iowa and North Carolina, is the largest US cohort study of individuals working with pesticides. The AHS cohort was enrolled in 1993 to 1997 to assess human health effects associated with well characterized exposures to pesticides and other agricultural factors. Detailed exposure data were collected at enrollment and in two five-year follow-up interviews. As a result, the AHS has a wealth of information on pesticide use by both farmers and their spouses, as well as the ability to account for changes in pesticide use over time. Information on medical history and important covariates was also collected at enrollment and in the follow-up interviews, and will continue to be collected over time. Only mortality and cancer incidence are updated annually through linkage to vital statistics and cancer registries; all other health outcomes are based on self-reported information from participants. The accuracy of self-reported health outcome information can vary from quite good (e.g., asthma) to poor (e.g., rheumatoid arthritis). In order to ensure high quality epidemiologic analyses, validation of self-reported disease is necessary prior to statistical analysis. To date, several health endpoints have been validated through follow-up with AHS participants and their physicians. The purpose of the current protocol is three-fold: 1) update information on medical history and other important covariates through follow-up interviews of the cohort; 2) validate self-reported diseases among cohort participants over the duration of cohort follow-up (at least through 2020); and 3) complete initial contact of potential participants to inform them of other health outcome studies being conducted by an outside institution.

Currently, investigators plan to contact AHS cohort members to complete a follow-up interview allowing one of three modes of response: self-administered paper questionnaire, self-administered web survey (CAWI), and interviewer-administered telephone interview (CATI). Study staff will contact proxy respondents if the participant is unable to provide information.

While the characteristics of the diseases may vary, the strategy for disease validation is similar. Validation efforts will include a phone call to the participant to confirm the self-report, a short questionnaire about disease characteristics, a request for permission to contact the participant's physician, and contacting the physician's office to obtain the relevant medical information. Study staff may also collect a saliva or cheek swab sample from cases who confirm their self-reported

disease to allow for future genetic and DNA analyses. These may include polymorphisms that influence disease susceptibility, response to xenobiotic agents, and innate immune response. Investigators will contact proxy respondents if the participant is unable to provide information. Currently study staff plan to contact participants who have reported a history of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and Sjogren's syndrome (SS). Over time, investigators plan to validate other diseases as they accrue in the cohort.

Research progress and rationale for continuation of the study:

A total of 317 subjects completed screening for the Parkinson's disease validation. Of these, 54 denied disease, 259 confirmed disease and for 3 disease status was uncertain at screening. Of those confirming disease, 117 agreed to medical record release and saliva collection, 121 agreed to medical record release only, 3 agreed to saliva collection only, and 22 refused medical record release and saliva collection. Checklists have been returned by 61% of the physicians who were mailed these requests. No subjects have withdrawn from the Parkinson's disease validation. There are still plenty of subjects to contact from the 89,000 originally enrolled in the larger study. Research is progressing as expected and the study may continue.

Changes in previously approved research:

Four amendments were approved during the past year, mostly for new or revised forms. The principal investigator is requesting the addition of Christie Barker-Cummings to the protocol and deletion of key research personnel from the study with this submission. In addition, Michael Jones, PhD (University of Iowa) and Eric Postel, MD (Duke University) have been removed as Associate Investigators.

Significant new findings:

There have been no new findings that would affect the IRB's evaluation of the study or the subject's willingness to continue participation in the research.

Protocol recruitment:

Since the last review by the NIEHS IRB a total of 314 subjects have been enrolled in the Parkinson's Disease Validation effort conducted under this protocol. The annual inclusion report provides the demographics of these subjects. The accrual numbers also include subject recruitment to the Autoimmune Validation and PD Validation sub-studies. The accrual information provided with the original submission was incorrect; however, the information was updated prior to the IRB's review. Subject selection remains equitable.

Summary of Adverse Events, Protocol Violations, Serious or Continuing Non-compliance and Unanticipated Problems:

There had been some issues in the previous reporting period but none in the present one.

Scientific design:

No changes in research have affected the scientific design.

Informed consent process is adequate and is appropriately documented (45 CFR 46.111(a)(4), 46.116 and 46.117):

Consent procedures continue to be adequate.

Additional safeguards for vulnerable subjects (45 CFR 46.111(a)(1)):

There are no vulnerable subjects in this study. Children are excluded.

Monitoring of data to ensure safety of subjects (45 CFR 46.111(a)(6)):

The study does not require a data safety and monitoring board. Subject safety is monitored by the PI.

Privacy & confidentiality (45 CFR 46.111(a)(7)):

There have been no changes in privacy and confidentiality which continue to be adequate.

Risks are reasonable in relationship to anticipated benefits/benefits, if any(45 CFR 46.111(a)(2):

There have been no changes in risk, and nothing has appeared in the literature that would change the IRB's assessment of the risks in relationship to benefit.

Period of Approval:

One year.

Additional considerations:

Approvals are included for off-site studies folded into this protocol as well as the approval from the Copernicus Group IRB.

From: [Maria DiCaprio](#)
To: [Bost, Patricia](#); [O'Connell, Elizabeth](#); [O'Connell, Elizabeth](#); [Bost, Patricia](#)
Subject: Study Closure Notification for Protocol 11-E-N196 (SSS1-11-220)
Date: Tuesday, April 21, 2015 1:58:21 PM

This protocol is now considered closed. If this is incorrect please contact Jason Garrett

Maria DiCaprio
Study Status Analyst I
Client Services

Copernicus Group IRB
One Triangle Drive, Suite 100
Research Triangle Park NC 27709
Direct: 919-287-6620

Toll Free: 888.303.2224

Fax number: 919-654-7197

<http://www.cgirb.com>

Don't have a Connexus account?

Visit the [Connexus website](#) or contact me for assistance!

Confidentiality Notice: This e-mail message, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.



**DO NOT submit this form
unless you intend for your
site to be closed with
Copernicus Group IRB**

Submit this form directly to CGIRB via [Connexus](#)

Blank & Incomplete Answers Will Result in Delayed Reviews

- Please complete this Principal Investigator Site Closeout Report if your study is closed or otherwise terminated and submit to CGIRB for review. Upon closure, acknowledgement will be sent.
 - Do **not** use this form for principal investigator (PI) transfers. Complete the **Principal Investigator Transfer Form**, located on the CGIRB website (<http://www.cgirb.com>).
- If you have additional sites participating in this CGIRB-approved study, you should not submit this form until all of the sites have completed all study-related activities.
- Note: CGIRB processes all events that are reportable under CGIRB's promptly reportable information policy for up to 6 months after study/site closure.
- Refer to the **CGIRB Investigator Guidebook** for additional information about study closure at a PI site.

Protocol #: 11-E-N196	IRB Tracking #: SSS1-11-220
Principal Investigator (PI):	Dale Sandler, Ph.D.
Site/Center Name:	NIEHS
PI Phone # 919-541-4668	PI Fax # 919-541-2511
PI E-mail: sandler@niehs.nih.gov	

SECTION 1:

This research study is: **Please select one:**

<input type="checkbox"/>	Closed	<u>NO</u> subjects were screened or enrolled. Complete and date section 3 and submit. (Do NOT complete section 2.)
<input type="checkbox"/>	Closed	Subjects were enrolled and have completed all applicable study visits; No Active subjects remain in the study (including subjects being followed for any reason, e.g. safety follow-up) Complete sections 2 and 3.
<input checked="" type="checkbox"/>	Closed	Other (specify) OHSRP approved reliance agreement with NIH as the IRB of record, no longer requiring review and approval by CGIRB Complete sections 2 and 3. Attach additional documentation as necessary.

If enrollment is closed but you expect subjects to remain active in the study (eg, completing remaining study visits) you MAY NOT close your site.



Immediate Response Required
Principal Investigator Site Closeout Report



SECTION 2:

Since the START of the study or most recent continuing review:

YES NO

Table with 3 columns: Question ID, Question Text, YES, NO. Contains items 2A through 2G regarding unanticipated problems, changes/modifications, complaints, compensation, FDA/OHRP inspections, state medical license, and new findings.

SECTION 3:

By submitting this form, I am confirming that I am the Principal Investigator (PI) or the PI's designee authorized to submit on behalf of the PI. The information within this form is accurate and complete with the PI's full awareness of the information submitted.

eoconnell@s-3.com

Submitter's e-mail address

Elizabeth O'Connell

Study Manager

21Apr2015

Name of Individual at Site Completing Form

Title of Individual at Site Completing Form

Date

For questions, you may contact CGIRB at (888) 303-2224. For the best service, have your IRB tracking number ready